Its use is approved for basal cell skin cancer and actinic keratosis, a precursor condition of squamous cell carcinoma of the skin. At present, the best evidence for the use of imiquimod
for melanoma or lentigo maligna
are only case reports. While the results of these studies are promising, only a few patients have been studied and the quality of evidence is weak. Common side effects to Aldara involve skin reactions in the area where it was applied.